Genentech secures FDA breakthrough therapy designation for Esbriet to treat uILD
Esbriet is an oral medication intended to treat people with idiopathic pulmonary fibrosis and is available in more…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Mar 20
Esbriet is an oral medication intended to treat people with idiopathic pulmonary fibrosis and is available in more…
In October 2018, then-home secretary Sajid Javid passed a law making the use of medicinal cannabis to treat…
28 Feb 20
GSK has also partnered with a consortium of non-profit organisations to advance the development of novel ‘pan-TB’ drug…
27 Feb 20
The sNDA approval was supported by the results from Phase 3 NALA trial, which evaluated the neratinib in…
25 Feb 20
Perrigo has collaborated with its development and manufacturing partner Catalent Pharma Solutions to speed up the production
In clinical trials, the new IV treatment was shown to reduce symptoms of migraines — including headaches, nausea…
24 Feb 20
Trulicity is indicated for major adverse cardiovascular events (MACE) in type 2 diabetes patients, with cardiovascular (CV) disease…
24 Feb 20
The Phase 3 ATTRACTION-3 clinical trial, which evaluated Opdivo compared to chemotherapy, has supported the Japanese regulatory approval
20 Feb 20
The combination of PADCEV and KEYTRUDA is indicated as treatment for unresectable metastatic urothelial cancer in patients
20 Feb 20
Tecentriq is an initial monotherapy for patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC)